Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company.

November 4, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company. We would like to inform you that a proposal to transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company has been approved by the board of directors of the respective companies, and also the Company in its meeting held today, November 4, 2026. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure. The Board meeting commenced at 4:15 p.m and concluded at 6:00p.m. Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Annexure a Name of the target entity, details in brief such Auro Pharma LLC, Russia (“Auro Pharma”), a step- as size, turnover etc.; down subsidiary of the Company in which Auroactive Pharma Private Limited (“Auroactive Pharma”), a wholly owned subsidiary of the Company, is holding 100% stake. Transfer of entire 100% stake of Auro Pharma from Auroactive Pharma to Auropharm Overseas Limited (“Auropharm Overseas”), a wholly owned subsidiary of the Company. The turnover of Auro Pharma, Auroactive Pharma and Auropharm Overseas for the financial year ended March 31st 2026 is as under: Name of the company Turnover for FY 2026 (INR million) Auro Pharma LLC Nil Auroactive Pharma Pvt. Ltd. 701.3 Auropharm Overseas Ltd. Nil b Whether the acquisition would fall within Auro Pharma, Auroactive Pharma and Auropharm related party transaction(s) and whether the Overseas are wholly owned subsidiaries promoter/ promoter group/ group companies (directly/indirectly) of the Company and related parties to each other. The transaction is undertaken have any interest in the entity being acquired? If at an arm’s length price. yes, nature of interest and details thereof and whether the same is done at “arm’s length”; It may be noted that since the transaction is between two wholly owned subsidiaries of the Company, it is exempt from the applicability of provisions of Regulations 23(2), (3) and (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. c Industry to which the entity being acquired Manufacturing / marketing of pharmaceutical belongs; products. d Objects and impact of acquisition (including The proposed share transfer is undertaken as part of but not limited to, disclosure of reasons for an internal reorganization exercise to streamline the acquisition of target entity, if its business is holdings of the Russian subsidiary within the group outside the main line of business of the listed companies. entity); e Brief details of any governmental or regulatory No governmental or regulatory approvals required. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com approvals required for the acquisition; f Indicative time period for completion of the 60-90 days subject to customary corporate and acquisition; transfer formalities. g Consideration - whether cash consideration or Cash consideration of ~INR 29 cr. subject to share swap or any other form and details of the adjustments, as agreed between the Parties, as on same; the date of transfer. h Cost of acquisition and/or the price at which INR 29 crores the shares are acquired; i Percentage of shareholding / control acquired 100% and / or number of shares acquired; j Brief background about the entity acquired in Auro Pharma is a step-down subsidiary of the terms of products/line of business acquired, Company incorporated on July 24, 2023, in Russia date of incorporation, history of last 3 years for manufacturing and marketing pharmaceutical turnover, country in which the acquired entity products. has presence and any other significant Turnover of Auro Pharma for the last 3 years information (in brief); Year Turnover (Rs. in million) 2025-26 Nil 2024-25 Nil 2023-24 Nil Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com